Q&A: Why the Jury Is Still Out on Durvalumab for NMIBC
Summary
Despite a recent FDA approval, urologic oncologists are waiting for more data before embracing durvalumab add-on for patients with high-risk non-muscle invasive bladder cancer.
Description from Medscape.
Who is covering this
-
Q&A: Why the Jury Is Still Out on Durvalumab for NMIBC
Despite a recent FDA approval, urologic oncologists are waiting for more data before embracing durvalumab add-on for patients with high-risk non-muscle invasive bladder cancer.






Comments
Comments need JavaScript.